SCHEMBL4055581

SCHEMBL4055581

FC(F)(F)c1cccc(-c2nc3ncc(-c4ccco4)cc3[nH]2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
THRB P10828 1/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
STAT6 P42226 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SCN2A Q99250 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062195 0.86 MGAM (0.45) AURKAPIN1BRAFMAPK13RAF1
SCHEMBL4239405 0.85 GABRA1 (0.43) AURKABRAF
SCHEMBL4057030 0.83 SCN2A (0.53) CYP1A2CYP3A4CYP2C9KDM4EMEN1
SCHEMBL4050957 0.83 IKBKE (0.49) KDM4ENPC1ALDH1A1HPGDTSHR
SCHEMBL4050442 0.83 GUSB (0.46) SCN2AAURKAPARP1PIN1HRH1
SCHEMBL4060508 0.83 PTGES (0.45) KDM4EMEN1NPC1ALDH1A1PKM
SCHEMBL13608579 0.82 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C9KDM4EMEN1
SCHEMBL4058461 0.81 SCN2A (0.56) CYP1A2CYP3A4CYP2C9KDM4EMEN1
SCHEMBL4058112 0.81 AURKA (0.58) AURKA
SCHEMBL4055195 0.81 AURKA (0.60) CYP1A2CYP2C9KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B CYP1A2 617/4885CYP3A4 886/4885CYP2C9 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.